Abstract Current therapeutic approaches to treatment of patients with bulky cervical cancer are based on conventional in situ ablative modalities including cisplatin-based chemotherapy and radiation therapy. The 5-year survival of patients with nonresectable disease is dismal. Because over 99% of squamous cervical cancer is caused by persistent infection with an oncogenic strain of human papillomavirus (HPV), particularly type 16 and viral oncoproteins E6 and E7 are functionally required for disease initiation and persistence, HPV-targeted immune strategies present a compelling opportunity in which to demonstrate proof of principle. Sublethal doses of radiation and chemotherapeutic agents have been shown to have synergistic eVect in combination with either vaccination against cancer-speciWc antigens, or with passive transfer of tumor-speciWc cytotoxic T lymphocytes (CTLs). Here, we explored the combination of low-dose radiation therapy with DNA vaccination with calreticulin (CRT) linked to the mutated form of HPV-16 E7 antigen (E7(detox)), CRT/E7(detox) in the treatment of E7-expressing TC-1 tumors. We observed that TC-1 tumor-bearing mice treated with radiotherapy combined with CRT/E7(detox) DNA vaccination generated signiWcant therapeutic antitumor eVects and the highest frequency of E7-speciWc CD8 + T cells in the tumors and spleens of treated mice. Furthermore, treatment with radiotherapy was shown to render the TC-1 tumor cells more susceptible to lysis by E7-speciWc CTLs. In addition, we observed that treatment with radiotherapy during the second DNA vaccination generated the highest frequency of E7-speciWc CD8 + T cells in the tumors and spleens of TC-1 tumor-bearing mice. Finally, TC-1 tumor-bearing mice treated with the chemotherapy in combination with radiation and CRT/E7(detox) DNA 
Introduction
Despite the fact that it has been possible to screen for cervical cancer for 60 years, this disease is still the second most common cause of cancer death in women worldwide. Persistent infection with an oncogenic strain of human papillomavirus (HPV), most commonly, type 16 , causes essentially all squamous cervical cancers. Expression of two viral proteins, E6 and E7, is functionally required for disease initiation and persistence, thereby presenting compelling antigenic targets for therapeutic immunization.
We have developed several targeting strategies for therapeutic DNA vaccines for HPV disease. However, while DNA vaccines present an attractive approach for therapeutic HPV vaccine development because of the ability to engineer exquisite antigen speciWcity, in humans, to date, potency of vaccination alone has been limited.
We have developed several strategies to enhance potency, by using intracellular targeting strategies to enhance MHC class I/II antigen presentation and processing in dendritic cells (DCs), and by targeting the DNA into DC in vivo by using particle-mediated epidermal delivery (PMED). We have engineered a DNA construct consisting of a pNGVL4a vector containing a mutated form of the HPV16 E7 antigen linked to caltreticulin (CRT). The E7 antigen in this construct has been modiWed at aa24 and 27, which completely abrogates function while retaining conformation, so that CD8 + T cells elicited by this construct demonstrate antitumor eVect against epithelial cells expressing wildtype E7. Calreticulin (CRT) is a 46-kDa Ca 2+ -binding chaperonin related to the family of heat shock proteins (HSPs) [4, 8, 23] . It promotes assembly of MHC Ipeptide complexes delivered into the endoplasmic reticulum by transporters associated with antigen processing (TAP-1 and TAP-2) [28] , and also complexes with MHC class I-2m molecules to aid in antigen presentation [27] . Moreover, CRT and its protein fragment (aa 1-180), vasostatin, have been shown to selectively inhibit vascular endothelial cell proliferation, and to suppress tumor growth. We showed previously that homologous prime-boost vaccination with this construct is eVective in enhancing E7-speciWc CD8 + T cell responses which are capable of eliminating established E7-expressing epithelial tumors, (TC-1) [6, 17] . This vaccine is in phase I testing for patients with early stage, operable (IB1) cervical cancer. (GOG 0702).
More recently, emerging preclinical and clinical evidence suggests that DNA vaccines are a reasonable choice for priming vaccination. In particular, a growing body of evidence suggests that conventional cancer treatment modalities can be combined with immune therapies in a synergistic manner. In fact several clinical studies have employed the combination of radiotherapy with immunotherapy and have been shown to induce tumor-speciWc and innate immunity [7, 13] .
Current clinical strategies for the treatment of (greater than stage IB2) bulky disease primarily involve non-surgical therapies, including radiation and/or cisplatin-based chemotherapy. Sublethal radiation has been shown to increase immunogenicity of solid tumors by several mechanisms, including enhancing the expression of MHC class I molecules [25] , as well as increasing expression of adhesion molecules by endothelial cells [10] . These and other phenotypic changes subsequent to radiation render established disease more susceptible to T-cell-mediated lysis [9, 11] . Chemotherapeutic regimens, including cisplatin (CDDP) can also render solid tumors more susceptible to immunologic intervention [11, 20] .
In the current study, we explored the combination of radiotherapy with CRT/E7(detox) DNA vaccination in the treatment of E7-expressing TC-1 tumors. We observed that TC-1 tumor-bearing mice treated with radiotherapy combined with CRT/E7(detox) DNA vaccination generated better therapeutic antitumor eVects and higher frequency of E7-speciWc CD8 + T cells compared to treatment with DNA vaccination or radiation alone. Since, in the clinical setting, patients with advanced cervical cancer receive chemoradiation therapy, we also tested the combination of chemoradiation with CRT/E7(detox) vaccination in TC-1 tumor-bearing mice. We found that TC-1 tumor-bearing mice treated with the chemoradiation in conjunction with CRT/E7(detox) DNA generate signiWcantly enhanced therapeutic antitumor eVects. The clinical implications of the study are discussed.
Materials and methods

Mice
Female C57BL/6 mice (5-8 weeks old) were obtained from the National Cancer Institute (Frederick, MD) and maintained in the oncology animal facility of the Johns Hopkins Hospital (Baltimore, MD). All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Cell line
BrieXy, TC-1 cells were obtained by co-transformation of primary C57BL/6 mouse lung epithelial cells with HPV-16 E6 and E7 and an activated ras oncogene as described previously [18] . Although TC-1 tumor cells are not a true cervical cancer cell line, they serve as a suitable model for the development of therapeutic HPV vaccines since they rely on E6 and E7 for their oncogenicity. The expression of E7 in TC-1 cells has also been characterized previously by He et al. [14] .
DNA constructs
The generation of DNA vaccine encoding CRT and E7(detox) has been described previously [17] . BrieXy, pNGVL4a-CRT/E7(detox), was generated by PCR ampliWcation of CRT by primers (5Ј-AAAGTCGACATGCTGCT ATCCGTGCCGCTGC -3Ј and 5Ј-GAATTCGTTGTCTG GC-CGCACAATCA-3Ј) using a human CRT plasmid as a template. The PCR product was digested with SalI/EcoRI and cloned into the SalI/EcoRI sites of pNGVL4a-E7(detox). The accuracy of DNA constructs was conWrmed by DNA sequencing.
Particle mediated epidermal delivery of DNA vaccine DNA-coated gold particles were prepared, and gene gun particle-mediated DNA vaccination was performed, according to a protocol described previously [5] . Gold particles coated with DNA vaccines (1 g DNA/bullet) were delivered to the shaved abdominal regions of mice by using a helium-driven gene gun (Bio-Rad Laboratories Inc., Hercules, CA) with a discharge pressure of 400 lb/in 2 . C57BL/ 6 mice (5 per group) were immunized with 2 g of the DNA vaccine and received two boost vaccinations with the same dose at 4-day intervals.
In vivo tumor treatment regimens
Sequential radiation and vaccination
To assess in vivo tumor treatment regimens, 9 £ 10 4 TC-1 tumor cells/mouse were injected subcutaneously in the right Xank area into 5-8 week-old C57BL/6 mice (5 per group). After 8 days, the mice were divided into groups (5 per group) reXecting diVerent treatment regimens: Group 1 received TC-1 tumor challenge alone; Group 2 was treated with radiation (14 Gy) at day 6; Group 3 was vaccinated with 2 mcg of 4a-CRT/E7 DNA on days 8, 12 and 16; and Group 4 was treated with radiation (14 Gy) on day 6 and then subsequently immunized with 2 mcg of 4a-CRT/E7 DNA on days 8,12, and 16. Mice were monitored twice a week by inspection and palpation. Survival curves on day 63 are shown. Tumor size was monitored by measuring the longest dimension (length) and shortest dimension (width) in a 3-day interval with a dial caliper. Tumor volume was calculated by the following formula: tumor diameter = 0.5£ (length + width). At the end of the experiment, mice were killed if tumor size was greater than 2 cm [3] .
Radiation combined with vaccination
Groups of C57BL/6 mice (5 per group) were challenged with 9 £ 10 4 TC-1 tumor cells on day 0 and immunized with the 4a-CRT/E7 DNA vaccine on days 8, 12, and 16. Mice were treated with (1) radiotherapy followed by DNA vaccination (RT-DDD), (2) radiotherapy administered on the day of the Wrst vaccination (D-RT-DD), or (3) radiotherapy administered on the day of the second vaccination (DD-RT-D).
Sequential chemoradiation and vaccination
C57BL/6 mice (5 per group) were subcutaneously challenged with 5£10 4 /mouse of TC-1 tumor cells over the left frontal thigh on D0. Tumor-challenged mice were treated with chemoradiation (cisplatin (5 mg/kg) and radiotherapy (14 Gy)) on day 10 and vaccinated with 2 g 4a-CRT/E7, on days 11, 15, and 19. Cisplatin was intraperitoneally injected at a dose of 5 mg/kg bodyweight. The administered doses were diluted with PBS solution to the required concentration and injected in volumes of 200 l. Mice treated with vaccination alone were used as a control.
Preparation of single-cell suspensions from tumors Solid tumors were surgically excised under sterile conditions free of surrounding normal tissue and placed in RPMI 1640 containing 1% antibiotic/antimycotic on ice, and washed with PBS. Tumors were then minced into 1-2-mm pieces and centrifuged at 1,800 rpm for 10 min, and supernantants were removed. After repeating the centrifugation, the tumor fragments were incubated for 45 min to 1 h in a digestion solution (5 ml/g tissue) containing 1 mg/ml trypsin, 1 mg/ml collagenase D, and 0.25 mg/ml DNase in HBSS in an atmosphere of 5% CO 2 at 37°C. Pipetting of the samples every 15 min substantially enhanced tissue disruption. DMEM containing 10% FCS and 1% antibiotic/ antimycotic was added to the cell suspension to stop the enzymatic activity. To lyse red blood cells, the tissue digests were brieXy exposed to cold Tris NH4Cl, washed, and Wltered through a 70-m nylon Wlter mesh to remove undigested tissue fragments, resulting in a single-cell suspension. The resultant single tumor cell suspensions were washed twice in HBSS (400£g for 10 min), and viable cells puriWed using single step Ficoll-Hypaque gradients. The gradient interfaces, containing viable tumor cells, lymphocytes and monocytes, were harvested and washed twice with HBSS. The total number of viable cells was then determined using trypan blue dye exclusion and the cells were cryopreserved [31] .
Characterization of apoptotic cell death
For characterization of the apoptotic cell death, 2 £ 10 5 TC-1 cells were injected s.c. into the frontal thigh of C57BL/6 mice (5 per group). On day 14, the tumors in the mice were treated with the diVerent doses of radiotherapy; 14 or 36 Gy. Mice were killed 5 days later and the tumors were isolated and single-cell suspensions were prepared as described above. Three hours later, they were stained with PE-conjugated annexin V antibody (BD Pharmingen, San Diego, CA, USA). Flow cytometry analysis was performed to characterize the expression of annexin V positive (apoptotic) cells among the irradiated TC-1 tumor cells. The isotype-matched control antibody was used as the negative control. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA, USA).
Intracellular cytokine staining and Xow cytometry analysis
Pooled splenocytes from tumor bearing and naïve mice treated with the various treatment regiments were harvested 7 days after the last treatment and incubated for 20 h with 1 g/ml of E7 peptide containing an MHC class I epitope (aa49-57, RAHYNIVTF) in the presence of GolgiPlug (BD Pharmingen, San Diego, CA, USA) [16] . The stimulated splenocytes were then washed once with FACScan buVer and stained with phycoerythrin-conjugated monoclonal rat anti-mouse CD8a (clone 53.6.7). Cells were subjected to intracellular cytokine staining using the CytoWx/Cytoperm kit according to the manufacturer's instruction (BD Pharmingen, San Diego, CA, USA). Intracellular IFN-was stained with FITC-conjugated rat anti-mouse IFN-. All antibodies were purchased from BD Pharmingen. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA, USA).
In vitro CTL assays
Luciferase-expressing TC-1 cells [15] in medium were seeded into a 24-well round-bottom plate (5 £ 10 4 cells/ well). The TC-1 tumor cells were treated with a radiation (RT) dose of 388 rad and incubated in 5% CO 2 for 24 h at 37°C. E7-speciWc cytotoxic T lymphocytes (CTL) from the spleens of tumor-bearing mice immunized with the DNA vaccine served as eVector cells and were added in the amount of 1 £ 10 6 cells/well. TC-1 cells expressing luciferase were used as target cells. After incubation, D-luciferin (potassium salt; Xenogen Corp.) was added to each well at 150 g/ml in media 7-8 min before imaging with the Xenogen IVIS 200 system. CTL-mediated killing was assessed using bioluminescence imaging systems quantitating the decrease of luminescence from baseline.
Statistical analysis
Data presented as mean § standard error (SE) are representative of at least two diVerent experiments. All P values < 0.05 were considered signiWcant. Statistical analysis was performed using T test for independent samples. Survival distributions for mice in diVerent groups were compared by the Kaplan-Meier curves and by use of the long-rank tests. Analyses were performed using SigmaPlot software (Systat software, Inc.).
Results
TC-1 tumor-bearing mice treated with radiotherapy combined with CRT/E7(detox) DNA vaccination generate the best therapeutic antitumor eVects
To determine the therapeutic antitumor eVects generated by radiotherapy combined with vaccination with DNA encoding CRT/E7(detox), we Wrst challenged groups of C57BL/6 mice (5 per group) with TC-1 tumor cells and then treated them with DNA vaccine alone, radiotherapy alone, or radiotherapy in combination with DNA vaccination as illustrated in Fig. 1a . As shown in Fig. 1b , tumor-bearing mice treated with radiotherapy in combination with CRT/E7(detox) DNA showed signiWcantly reduced tumor size over time as compared to tumor-bearing mice treated with radiotherapy alone or the DNA vaccine alone (P = 0.001). Furthermore, tumor-bearing mice treated with radiotherapy in combination with CRT/E7(detox) DNA showed improved survival compared to tumor-bearing mice treated with radiotherapy alone or the DNA vaccine alone (P = 0.003) (Fig. 1c) . Thus, our data indicate that the treatment regimen using radiotherapy in combination with CRT/E7(detox) DNA produces the best therapeutic antitumor eVects and long-term survival in TC-1 tumor-bearing mice.
Treatment of TC-1 tumor cells from tumor-bearing mice with radiotherapy enhances the apoptotic tumor cell death In order to determine the eVect of radiotherapy on TC-1 tumor cells in tumor-bearing mice, we isolated TC-1 tumor cells from tumor-bearing mice treated with diVerent doses of radiation. The cells were then characterized for apoptotic cell death using annexin V staining. As shown in Fig. 2 , we observed that TC-1 tumor cells treated with the higher doses of radiotherapy demonstrated a greater degree of apoptotic tumor cell death compared to control untreated TC-1 tumor cells. Thus, our data indicate that radiotherapy enhances the apoptotic tumor cell death in TC-1 tumors.
TC-1 tumor-bearing mice treated with radiotherapy combined with CRT/E7(detox) DNA generate highest frequency of E7-speciWc CD8 + T cells
In order to determine the E7-speciWc CD8 + T cell immune response in tumor-bearing mice treated with radiotherapy in combination with the CRT/E7(detox) DNA vaccine, we Wrst challenged groups of C57BL/6 mice (5 per group) with TC-1 tumor cells and then treated them with DNA vaccine alone, radiotherapy alone, or radiotherapy in combination with DNA vaccination as illustrated in Fig. 1a . Seven days after the last treatment, we harvested splenocytes from vaccinated mice and characterized the presence of E7-speciWc CD8 + T cells in treated mice using intracellular cytokine staining for IFN-followed by Xow cytometry analysis. As shown in Fig. 3 , tumor-bearing mice that were treated with radiotherapy in combination with CRT/E7(detox) DNA generated a signiWcantly higher number of E7-speciWc CD8 + T cells compared to tumor-bearing mice that were administered CRT/E7(detox) DNA alone, or radiotherapy alone (P = 0.058). These results indicate that treatment of tumor-bearing mice with radiotherapy in combination with CRT/E7(detox) DNA leads to the strongest E7-speciWc CD8 + T cell immune response. In order to determine the E7-speciWc CD8 + T cell immune response in the tumor inWltrating lymphocytes (TILs) of tumor-bearing mice treated with radiotherapy in combination with the CRT/E7(detox) DNA vaccine, we Wrst challenged groups of C57BL/6 mice (5 per group) with TC-1 tumor cells and then treated them with DNA vaccine alone, radiotherapy alone, or radiotherapy in combination with DNA vaccination as illustrated in Fig. 1a . Seven days after the last treatment, we harvested the TILs from vaccinated mice and characterized the presence of E7-speciWc CD8 + T cells in treated mice using intracellular cytokine staining for IFN-followed by Xow cytometry analysis. As shown in Fig. 4 , tumor-bearing mice that were treated with radiotherapy in combination with CRT/E7(detox) DNA generated a signiWcantly higher number of E7-speciWc CD8 + T cells in the TILs compared to tumor-bearing mice that were administered CRT/E7(detox) DNA alone or radiotherapy alone (P = 0.006). These results indicate that treatment with radiotherapy in combination with CRT/E7(detox) DNA leads to the strongest E7-speciWc CD8 + T cell immune response in the TILs of tumor-bearing mice.
Treatment with radiotherapy renders the TC-1 tumor cells more susceptible to lysis by E7-speciWc CTLs
In order to determine if treatment of TC-1 tumor cells with radiotherapy will render the tumor cell more susceptible to E7-speciWc T cell-mediated killing, we performed a cytotoxicity assay using luciferase-expressing TC-1 tumor cells. TC-1 tumor cells were treated with radiotherapy alone, radiotherapy and E7-speciWc cytotoxic T cells (CTL), or treated with E7-speciWc CTLs alone. Untreated TC-1 tumor cells were used as a control. The CTL-mediated killing of the TC-1 tumor cells in each well was monitored using bioluminescent imaging systems. The degree of CTL-mediated killing of the tumor cells was indicated by the decrease of luminescence activity. As shown in Fig. 5 , the lowest luciferase activity was observed in the wells incubated with radiotherapy and E7-speciWc CTLs as compared to the wells incubated with radiotherapy alone or E7-speciWc CTLs alone (P = 0.002). Thus, our data suggest that the TC-1 tumor cells treated with radiotherapy increased the susceptibility of the tumor cells for lysis by the E7-speciWc cytotoxic T cells.
Treatment with radiotherapy during the second DNA vaccination generates highest frequency of E7-speciWc CD8 + T cells in the tumors and spleens of TC-1 tumor-bearing mice In order to determine the E7-speciWc CD8 + T cell immune response in the tumors and spleens of tumor-bearing mice treated with radiotherapy in combination with the CRT/ E7(detox) DNA vaccine, we Wrst challenged groups of C57BL/6 mice (5 per group) with TC-1 tumor cells and then treated them with radiotherapy in combination with DNA vaccination using diVerent regimens as illustrated in Fig. 6a . Seven days after the last treatment, we harvested the splenocytes and the TILs from vaccinated mice and characterized the presence of E7-speciWc CD8 + T cells in treated mice using intracellular cytokine staining for IFNfollowed by Xow cytometry analysis. As shown in Fig. 6b , tumor-bearing mice that were treated with radiotherapy during the second CRT/E7(detox) DNA vaccination generated a signiWcantly higher number of E7-speciWc CD8 + T cells in the splenocytes (P = 0.001) (Fig. 6c) and TILs (P = 0.015) (Fig. 6d) compared to tumor-bearing mice that were treated with radiotherapy during the Wrst DNA vaccination or before DNA vaccination. These results indicate that treatment with radiotherapy during the second CRT/ E7(detox) DNA vaccination leads to the strongest E7-speciWc CD8 + T cell immune response in the spleens and tumors of tumor-bearing mice. We also followed the tumor growth and survival in tumor-bearing mice treated with the diVerent regimens. Interestingly, we observed that tumorbearing mice treated with radiation before the Wrst DNA vaccination demonstrated signiWcantly lower tumor size compared to tumor-bearing mice treated with radiotherapy during the Wrst or second DNA vaccination (See Supplementary Fig. 1) .
In order to determine the E7-speciWc CD8 + T cell immune response in naïve mice treated with the similar regimens of radiotherapy in combination with the CRT/ E7(detox) DNA vaccine, we treated naïve mice using the regimen similar to the one described above (See Supplementary Fig. 2a) . We then harvested the splenocytes from vaccinated mice 7 days after the last treatment, and characterized the presence of E7-speciWc CD8 + T cells using intracellular cytokine staining for IFN-followed by Xow cytometry analysis. We observed that mice that were treated with radiotherapy during the second DNA vaccination generated a signiWcantly higher number of E7-speciWc CD8 + T cells compared to mice that were administered CRT/E7(detox) DNA alone (P = 0.039) ( Supplementary  Fig. 2b and c) . Taken together, our results indicate that mice treated with radiotherapy during the second CRT/ E7(detox) DNA vaccination demonstrate the strongest E7-speciWc CD8 + T cell immune response.
TC-1 tumor-bearing mice treated with the combination of radiotherapy and chemotherapy and vaccinated with CRT/E7(detox) DNA generate potent therapeutic antitumor eVects
The standard therapy for cervical cancer employs chemoradiation using cisplatin in combination with radiotherapy. Thus, in order to determine the therapeutic antitumor eVects generated by the combination of radiotherapy and chemotherapy in CRT/E7(detox) DNA vaccinated mice, we Wrst challenged groups of C57BL/6 mice (5 per group) with TC-1 tumor cells and then treated them with the combination of radiotherapy and chemotherapy using cisplatin. One day later, mice were vaccinated with the CRT/E7(detox) DNA vaccine 3 times with 4-day intervals as illustrated in Fig. 7a . As shown in Fig. 7b , tumor-bearing mice treated with the combination of radiotherapy and chemotherapy and vaccination with CRT/E7(detox) DNA showed signiWcantly reduced tumor size over time as compared to tumor-bearing mice treated with radiotherapy and chemotherapy alone or the DNA vaccine alone (P = 0.009). Furthermore, tumorbearing mice treated with the combination of radiotherapy and chemotherapy and vaccination with CRT/E7(detox) DNA showed improved survival compared to tumor-bearing mice treated with radiotherapy and chemotherapy alone or the DNA vaccine alone (P = 0.002) (Fig. 7c) . We also found that the antitumor eVects generated by radiotherapy with CRT/E7(detox) DNA vaccination were quite comparable with the antitumor eVects generated by chemoradiation (cisplatin + radiation) with CRT/E7(detox) DNA vaccination (data not shown). Thus, our data indicate that the treatment regimen using chemoradiation in combination with CRT/E7(detox) DNA produces potent therapeutic antitumor eVects and long-term survival in TC-1 tumor-bearing mice.
Discussion
In the current study, we observed that TC-1 tumor-bearing mice treated with radiotherapy combined with CRT/ E7(detox) DNA vaccination generated higher frequency of E7-speciWc CD8 + T cells in the spleen and in TILs, resulting in better therapeutic antitumor eVects and in treated mice. We also showed that CRT/E7(detox) DNA vaccination can also be used in conjunction with chemoradiation to signiWcantly enhance the therapeutic antitumor eVects in tumor-bearing mice. Thus, the encouraging preclinical data suggests that CRT/E7(detox) DNA may potentially be used in conjunction with conventional chemoradiation therapy in patients with advanced stage cervical cancer. The fact that HPV is an etiological factor for cervical cancer has created an opportunity to control HPV-associated cervical cancer by vaccination against HPV. The prophylactic vaccines, while eVective, present essentially the same barriers to uptake as those for screening and early treatment, and are unlikely to signiWcantly change the burden of disease in the near future [21, 26] . In the meantime, because the expression of HPV viral antigens, E6 and/or E7 is necessary to maintain the malignant phenotype, from an immunologic standpoint, HPV-associated disease is a compelling target for the development of therapeutic vaccines. Thus, in order to accelerate the control of cervical cancer and treat currently infected patients, it is important to continue the development of therapeutic vaccines against HPV.
In the current study, we have used low-dose radiation (14 Gy) in combination with CRT/E7(detox) DNA vaccination to generate E7-speciWc CD8 + T cell immune responses and therapeutic antitumor eVects and in treated mice. A recent study by Ye et al. has characterized the dose eVect of a range of irradiation doses in mice with established, 7-mm-diameter TC-1 tumors, ranging from 10-50 Gy [30] . These authors also found that irradiation increased the sensitivity of tumor to therapeutic vaccination, and that doses of irradiation could be decreased and still remain eVective when used in combination with protein vaccines in combination with CpG adjuvant in mice. Thus, our results are consistent with previous studies.
In our study, we showed that radiotherapy followed by CRT/E7(detox) DNA vaccination generate the best therapeutic antitumor eVects compared to radiotherapy alone or DNA vaccination alone (See Fig. 1) . Previous studies have shown that conventional cancer treatment modalities, including chemotherapy and radiation, can have immunoadjuvant eVects [1, 2, 12, 24, 32] . However, the mechanisms by which these synergies occur are incompletely understood. Low-dose irradiation may enhance the immunogenicity and tumor inWltration with antigen-speciWc CD8 + T cells of E7-targeted vaccination in tumor-bearing hosts. In addition, radiation may also phenotypically modulate the tumor by upregulation of chemokines, MHC molecules, tumor-associated antigens, costimulatory molecules, thus making it easier for tumor speciWc T-cells to traYc to and recognize tumor [19, 22] . This may lower the threshold for immune mediated killing, which can increase the inXammatory inWltrate. Thus our data are consistent with the notion that tumor cell death induced by conventional cancer treatment modalities may have immunoadjuvant eVects.
We observed the tumor-bearing mice that were treated with radiotherapy before CRT/E7(detox) DNA vaccination (RT-DDD) demonstrated the lowest tumor load compared to tumor-bearing mice treated with radiotherapy during the Wrst DNA vaccination (D-RT-DD) or second DNA vaccination (DD-RT-D) (See Supplementary Fig. 1 ). Thus, our data suggest that there is no direct correlation between the tumor burden and the E7-speciWc CD8 + T cell immune responses in treated mice. A possible explanation for the signiWcant therapeutic eVect generated by treatment with radiation before DNA vaccination may be due to signiWcant control of tumor by radiation during the early stages of tumor growth. The observed enhancement in the E7-specifc CD8 + T cell immune responses in mice treated with radiotherapy during the second DNA vaccination (DD-RT-D) may be related to the amount of the E7 tumor antigen released in treated mice following radiotherapy, although we cannot exclude other possibilities.
The IFN-production in the tumor microenvironment may be important for the observed enhanced antitumor eVect generated by radiotherapy in conjunction with immunotherapy. Recently, Lugade et al. have demonstrated that radiation is capable of inducing IFN-production in the tumor microenvironment [19] . The IFN-present in the tumor microenvironment may lead to the upregulation of MHC class I in the tumor cells, resulting in increased tumor cell target recognition by the antigen-speciWc CD8 + T cells and increased T cell inWltration. All these factors may potentially contribute to the radiation-induced enhancement of antitumor immunity.
Our study demonstrated that chemoradiation combined with CRT/E7(detox) DNA vaccination generated signiWcantly potent therapeutic antitumor eVects against TC-1 tumors (See Fig. 7) . We have recently demonstrated that pretreatment with cisplatin enhanced E7-speciWc CD8 + T cell-mediated antitumor immunity induced by CRT/ E7(detox) DNA vaccination [29] . Pretreatment of the tumor with cisplatin was shown to lead to apoptosis of the tumor cells, causing the uptake of E7 antigen by the APCs and activation of E7-speciWc CD8 + T cells. Similarly, in the current study, we have shown that radiation leads to an increase in the apoptosis of the tumor cells, resulting in increased number of E7-speciWc CD8 + T cell precursors. Because the standard therapy for advanced cervical cancer employs chemoradiation, our data support the notion that the conventional chemoradiation therapy may be combined with HPV DNA vaccination to further improve antitumor eVects and survival of patients with advanced cervical cancer.
The DNA vaccine we evaluated was engineered to improve immunogenicity by two strategies; by enhancing MHC Class I processing and presentation via linkage of antigen to CRT, a chaperonin, and by using PMED to optimize delivery to relevant dendritic cells. While we are in the process of testing this construct clinically in a patient cohort with minimal residual disease, the Wnding that radiotherapy could improve the immunogenicity and eYcacy of targeted vaccination would be potentially useful for patients with inoperable disease.
